A health-economic analysis of porcine islet xenotransplantation

Xenotransplantation
Jessica BeckwithHenk-Jan Schuurman

Abstract

Islet cell transplantation is a promising treatment for type 1 diabetes. To overcome the shortage of deceased human pancreas donors, porcine islet cell xenotransplantation is being developed as an alternative to allotransplantation. The objective of this study was to perform a cost-effectiveness analysis of porcine islet transplantation in comparison with standard insulin therapy. The patient population for this study was young adults, ages 20 to 40, for whom standard medical care is inadequate in controlling blood glucose levels (hypoglycemia unawareness). Since trial data were lacking, estimates used extrapolations from data found in the literature and ongoing trials in clinical allotransplantation. Cost estimates were based on the data available in the USA. Markov modeling and Monte Carlo simulations using software specifically developed for health-economic evaluations were used. Outcomes data for ongoing clinical islet allotransplantation from the University of Minnesota were used, along with probabilities of complications from the Diabetes Control and Complications Trial. Quality-adjusted life years (QALYs) were the effectiveness measure. The upper limit of being cost-effective is $100,000 per QALY. Cost data from the lite...Continue Reading

References

Oct 9, 1996·JAMA : the Journal of the American Medical Association·L B RussellM C Weinstein
Sep 24, 1999·Archives of Internal Medicine·J B BrownA W Bakst
Jun 8, 2000·Medical Care·T O Tengs, A Wallace
Jul 21, 2001·Health Affairs·C HoganJ Lynn
May 27, 2003·Diabetes Care·Adam GordoisJanet Ash Tobian
Mar 30, 2004·Diabetes Care·Monica Maria OrtegonLouis Wilhelmus Niessen
Aug 4, 2004·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·B P TabaeiW H Herman
Sep 24, 2004·Diabetes/metabolism Research and Reviews·Ulrik Pedersen-BjergaardBirger Thorsteinsson
Sep 29, 2004·PharmacoEconomics·Frederick B DongMichael M Engelgau
Dec 24, 2005·The New England Journal of Medicine·David M NathanUNKNOWN Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research
Sep 29, 2006·The New England Journal of Medicine·A M James ShapiroJonathan R T Lakey
Sep 18, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·A D KirkH M Kauffman
May 2, 2008·Xenotransplantation·Henk-Jan Schuurman
Dec 27, 2008·Journal of Hepato-biliary-pancreatic Surgery·Hirohito Ichii, Camillo Ricordi
Oct 23, 2009·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D J van der WindtM Trucco

❮ Previous
Next ❯

Citations

Apr 12, 2012·Clinical Microbiology Reviews·Joachim Denner, Ralf R Tönjes
Aug 15, 2012·F1000 Medicine Reports·Adrianne L WongJulia L Greenstein
Nov 19, 2010·Regenerative Medicine·Adrianne L Wong, Concepcion R Nierras
Dec 17, 2010·Xenotransplantation·Mårten K J Schneider, Jörg D Seebach
Mar 28, 2013·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Sharon Grundfest-Broniatowski
Sep 1, 2016·Health Technology Assessment : HTA·Tracey Jones-HughesRob Anderson
Apr 26, 2016·Cell Transplantation·Bradley P WeegmanKlearchos K Papas
Nov 16, 2016·Journal of Diabetes Research·Bradley P WeegmanKlearchos K Papas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.